Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with chronic kidney disease who had not been on dialysis, and were not expected to begin dialysis, or renal transplantation in the next 4 months from the screening visit.~* Had serum phosphorus measurement greater than or equal to (\>=) 5.5 mg/dL (1.78 mmol/L) at screening visit (if participants were not on phosphate binder\[s\] at Screening Visit) OR at the end of Washout Period (if participants were on phosphate binder\[s\] at screening visit).~* Had the following laboratory measurements at screening visit:~  * 25-hydroxy vitamin D \>=10 nanograms per milliliter (ng/mL).~ * intact parathyroid hormone, intact parathyroid hormone (iPTH) \<=800 picograms per millilitre (pg/mL).~ * Signed written informed consent.~Exclusion criteria:~* Men or women below 18 years of age.~* Any technical/administrative reason that made it impossible to randomize the participant in the study.~* Was not of the level of understanding and willingness to cooperate with all visits and procedures, as described in the study protocol.~* Not yet received chronic kidney disease diet education before screening visit.~* Not willing and not able to avoid changes to diet during the study.~* Not willing or able to maintain screening doses of lipid lowering medication, 1, 25 dihydroxy vitamin D, and/or cinacalcet for the duration of the study, except for safety reasons.~* Not willing or not able to avoid antacids and phosphate binders containing aluminium, magnesium, calcium, or lanthanum for the duration of the study unless prescribed as an evening calcium supplement.~* Had participated in any other investigational drug studies within 30 days, or 5 half lives, whichever is longer, prior to screening visit.~* Conditions/situations such as:~  * Participant was the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.~ * Uncooperative or any condition that could make the participant potentially non-compliant to the study procedures (for example, participants could not be contacted by phones as required in phone call visits).~ * Evidence of active malignancy.~ * Not on stable medical condition (for example, but not limited to, active ethanol or drug abuse \[tobacco use acceptable\]; documented poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, human immunodeficiency virus \[HIV\] infection), or had any clinically significant medical conditions.~* Had known hypersensitivity to sevelamer or any constituents of Renvela tablets.~* Had bowel obstruction, active dysphagia or swallowing disorder, or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation.~* Using or plan to use anti-arrhythmic or anti-seizure medications for arrhythmia or seizure disorders.~* Was pregnant or breast-feeding.~* If the participant was female, and of childbearing potential (pre-menopausal and not surgically sterile), was not willing to use an effective contraceptive method throughout the study.~* Had any condition, which in the opinion of the investigator would prohibit the participant's inclusion in the study.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (\<=) 4.6 mg/dL (\<=1.49 mmol/L).
- Renvela (Type: EXPERIMENTAL): Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus \<=4.6 mg/dL (\<=1.49 mmol/L).

Based on this trial design, predict the completion outcome and termination type (if applicable).